Table 1.

Summary of published information on MAb 18B7

ParameterDescriptionComment and reference(s)
OriginMouse hybridomaThe hybridoma was generated by fusion of BALB/c splenocytes and NSO myeloma. For a description of hybridoma generation see reference 3. Although MAb 18B7 is not mentioned by name, it is one of the IgG1 MAbs described.
IsotypeIgG1The isotype was determined with rabbit alkaline phosphatase-conjugated isotype-specific antibodies (3).
Immunizing agentGXM-TTa conjugate vaccineGXM-TT vaccine was made and provided by the laboratory of John Robbins (Bethesda, Md.). For a description of GXM-TT see reference10.
Apparent affinity5 × 109M−1 Apparent affinity was measured by the method of Nieto et al. (42).
GXM serotype reactivityA > B > C > DRelative serotype reactivity was determined by inhibition ELISA (3).
Serological studiesReactivity with strain 24067 GXMMAb 18B7 antibody was shown to react with strain 24067 GXM by direct-binding ELISA, competition ELISA, and agglutination reaction with whole cells (55). MAb 18B7 was also shown to enhance the phagocytic and antifungal activity of J774.16 cells for strain 24067 (55).
Protection dataMurine intraperitoneal modelMice given MAb 18B7 lived significantly longer than control mice (33). The protective efficacy of 18B7 was comparable to that of 2H1 in the same mouse model (37).
VH VH7183 and JH2Heavy chain variable region usage was determined by sequencing of VH mRNA (33).
VL Vκ5.1 and Jκ1Light chain variable region usage was determined by sequencing of LH mRNA (33).
Construction of mouse-human chimeric antibodych18B7Chimeric mouse-human antibody was opsonic for human microglia and mouse J774.16 cells and prolonged survival of lethally infected mice (55).
Peptide mimotopeGLQYTPSWMLVGMAb 18B7 has been shown to bind a peptide mimotope of GXM in its antigen binding site (51).
Toxicity in primatesNoneMAb 18B7 was used as an isotype-matched control in studies of a therapeutic antibody that binds LPS (30).
  • a TT, tetanus toxoid.